Influence of antiviral therapy on survival of patients with hepatitis B-associated hepatocellular carcinoma undergoing transarterial chemoembolization

  • Bing Li
  • An Chen
  • Xilin Du
  • Jianxing Zhan
Keywords: Cancer, Chemoembolization, Hepatitis, Hepatocellular carcinoma, Transarterial chemoembolization (TACE)

Abstract

Purpose: To examine the prognostic value of antiviral therapy among hepatocellular carcinoma (HCC) patients undergoing transarterial chemoembolization (TACE).

Method: A total of 356 patients with HCC undergoing TACE were recruited for the purpose of current study. All the patients were categorized into two groups; antiviral (n = 132) and non-antiviral group (n = 224). All the clinical and laboratory parameters were noted at baseline. Patients were then followed up for five years. The mortality rates in two groups were evaluated with Kaplan-Meier estimate.

Results: The average age of the participants was 51.2 ± 6.17 years. A majority (329; 92.4 %) of the patients were male while females constituted only 7.6 %. During five years follow-up period, a total of 274 (76.9 %) died, with 89 patients belonging to the antiviral group while the remaining 185 patients were in the non-antiviral group. Mortality rate significantly differed between the antiviral and non-antiviral groups (67.4 % versus 82.5 %, p = 0.028). The results of Cox regression demonstrated that being a smoker, low serum albumin, local ablation and resection decreased overall survival while female gender, antiviral therapy, and early tumor site-node-metastatis (TNM) staging increased overall survival.

Conclusion: Antiviral therapy for underlying hepatitis B in HCC patients undergoing TACE prolongs overall survival and prevents or delays reactivation of tumor.

Keywords: Cancer, Chemoembolization, Hepatitis, Hepatocellular carcinoma, Transarterial chemoembolization (TACE)

Published
2017-09-07
Section
Articles

Journal Identifiers


eISSN: 1596-9827
print ISSN: 1596-5996